hotspot -WSS

hotspot

author：hotspot 2025-09-30 09:30:10 - browse：75

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Amazon expands telehealth clinic nationwide

explore

WSS

Vertex non

What the US credit downgrade means for the economy, your finances

Wildfire pollution widens asthma inequities on Long Island

The stability of $0 premiums in Medicare Advantage

Sage hopes for a blockbuster in antidepressant now before FDA

Mitch McConnell episode has important public health takeaway

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Some top drug companies are starting to take action on climate

As demand for Covid shots wanes, Moderna seeks its next success

Adults seen as increasingly susceptible to measles

Guidelines to prevent youth baseball injuries need more muscle

Micronoma's microbiome cancer diagnostic approach under fire

Bright Health sells Medicare Advantage business to Molina

Lawsuit alleges UnitedHealth Group unit illegally denied claims

New air purifier tech could be key to improving indoor air quality

Physician groups backed by private equity giant lobby on mergers

entertainment

Adults seen as increasingly susceptible to measles

What the airline industry can learn from medicine

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

6 solutions to address cancer drug shortages and others

The United States is paying nearly triple for new Covid vaccines

IVG is promising — but it won’t replace IVF quite yet

knowledge

hotspot

explore

knowledge